Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 26.7473
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 14258745720.0
- FreeCF/Share 1.0821
- PFCF 59.3578
- PE 89.3656
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers stock pops on Novo Nordisk partnership
Published: April 29, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Read More
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Published: April 29, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Read More
Hims & Hers partners with Novo Nordisk to sell Wegovy
Published: April 29, 2025 by: Fox Business
Sentiment: Positive
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Read More
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
Read More
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Published: April 29, 2025 by: Schwab Network
Sentiment: Negative
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the latest company following a formula.
Read More
HIMS stock spikes over 40%; Time to buy?
Published: April 29, 2025 by: Finbold
Sentiment: Positive
Summary ⚈ HIMS stock surged up to 45% after announcing a partnership with Novo Nordisk to offer Wegovy through its platform.⚈ The move positions Hims & Hers to capitalize on booming demand for weight-loss medications.
Read More
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Published: April 29, 2025 by: WSJ
Sentiment: Positive
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Read More
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Read More
Hims & Hers' stock rockets after teaming up with its rival Wegovy maker
Published: April 29, 2025 by: Market Watch
Sentiment: Positive
Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the maker of Wegovy.
Read More
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. As a first step, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy® and a Hims & Hers membership, which includes access to 24/7 care,.
Read More
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Published: April 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufacturing (an alternative to semaglutide) which will be able to recoup lost sales in its weight loss division after the FDA shortage of semaglutide ends. Hims trades at an appealing 18.1x EV/FY26 adjusted EBITDA, which is modest for a company growing revenue and adjusted EBITDA at a >60% y/y pace.
Read More
Hims & Hers: Top Pick For The Next Decade
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization and high CAC are strategic for long-term disruption in healthcare. HIMS boasts $209M in free cash flow, a 14% FCF margin, and positive net income, making it a financially robust small-cap company.
Read More
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension.
Read More
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
Read More
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
Read More
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Published: April 01, 2025 by: Investors Business Daily
Sentiment: Positive
Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.
Read More
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Published: April 01, 2025 by: Reuters
Sentiment: Positive
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
Read More
Here's why Hims & Hers stock price has crashed: buy the dip?
Published: March 27, 2025 by: Invezz
Sentiment: Negative
Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from its highest point this year.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.
Read More
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers (HIMS) is a newfangled tele-health company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one's given the stock a heck of ride; way up and then all the way back down. More big moves could happen in the near term. Looking deeper and reading a lot of tea leaves, I envision HIMS growing from a peddler of feel-good non-essential medications into a serious player in the emerging personalized medicine field.
Read More
Why Hims & Hers Stock Tumbled on Tuesday
Published: March 18, 2025 by: The Motley Fool
Sentiment: Negative
Hims & Hers Health (HIMS -6.95%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target on the pharmaceuticals stock in the worst way possible.
Read More
Why Hims & Hers Health Stock Just Popped
Published: March 11, 2025 by: The Motley Fool
Sentiment: Neutral
Roller-coaster healthcare stock Hims & Hers Health (HIMS 5.26%), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration (FDA) on Monday.
Read More
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% increase in subscribers and higher average revenue per subscriber. To mitigate risk, consider selling call options against HIMS shares, leveraging high implied volatility for a favorable risk-reward proposition.
Read More
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
Published: March 05, 2025 by: Barrons
Sentiment: Negative
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
Read More
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Positive
HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a tailwind, allowing its core personalized healthcare portfolio to shine, as observed in the double digits non-GLP-1 revenue growth. The same has been observed in the rich FY2024 performance metrics and the management's FY2025 guidance, as they seek to expand their vertically integrated healthcare offerings.
Read More
Why Hims & Hers Health Stock Sank This Week
Published: February 28, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Hims & Hers Health (HIMS 6.76%) sank 10.5% this week, according to data from S&P Global Market Intelligence. The telehealth company that sells dermatology, sexual health, and weight loss drugs directly to consumers posted strong growth for the fourth quarter of 2024 but has investors concerned over the legality of its weight loss drug compounds.
Read More
Wall Street's Most Wanted: 2 Highly Shorted Stocks Right Now
Published: February 26, 2025 by: MarketBeat
Sentiment: Negative
Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling shares short are hoping that the price of certain stocks falls so that they can make a profit.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637